


Curriculum Vitae

A. PERSONAL DETAILS			
1. Full name and ORCID account: Mina Thabet Gayed Kelleni https://orcid.org/0000-0001-6290-6025			
2. Citizenship and Religion: Egyptian, Christian			
3. Marital status and children: Married and blessed with two daughters; Elena 4-year-old and Eleanor 1.5-year-old.			
4. Cellphone: (+20) 1200382422			
5. E-mail: drthabetpharm@yahoo.com, mina.kelleni@mu.edu.eg			
6. Date of birth (day/month/year): 01/10/1981		7. Place of birth (City and Country): Minia, Egypt	
8. Current residential address: Shalaby district, Minia Egypt.			
B. EDUCATIONAL QUALIFICATIONS AND INTERESTS			
9. Field of study/discipline and specialization: Medicine, Pharmacology			
10. Tertiary academic qualifications:			
Degrees/diplomas obtained/underway	Field of study	Institution & location	Completion date
MBBS (bachelor's degree) WES ECA verified January 2020	Medicine and Surgery	College of medicine, Minia University, Egypt	February 2005
MSc (Pharmacology) WES ECA verified January 2020	Basic Medical Sciences (Pharmacology)	College of medicine, Minia University, Egypt	February 2011
MD/PhD (Pharmacology) WES ECA verified January 2020			February 2016
C. EMPLOYMENT HISTORY			
11. Employment experience:			
Name of employer & address	Position	Dates of employment	
College of Medicine, Minia University, Egypt	Demonstrator of Pharmacology	April 2006 to March 2011	
Al-Shefa Medical Center, Cairo, Egypt	General Practitioner and Dermatologist	March 2006 to December 2012	
Al-Muhaish Dispensary, Alhasa, Eastern province, KSA	Practicing Dermatologist (KSA MOH Licensed)	Jan 2013 to December 2013	

College of Medicine, Minia University, Egypt	Lecturer of Pharmacology	March 2011 to February 2016
College of Medicine, Minia University, Egypt	Assistant Professor of Pharmacology	March 2016 to Date
College of Medicine, Jouf University, KSA	Assistant Professor of Pharmacology	February 2018 to August 2019
College of Pharmacy, Jouf University, KSA		August 2019 to August 2020

12. Language skills, editorial board membership and professional honors:

IELTS (computer based) overall 7.5/9; Listening 8, Reading 9, Writing 6.5, Speaking 7 (July, 2019; First and only attempt)

TOEFL (iBT) 104/120; Reading 24 Listening 28 Speaking 24 Writing 28 (February, 2010, First and only attempt).

Youssef Jameel prize for scientific excellence awarded through the Egyptian Society of Pharmacology and Experimental Therapeutics (ESPET) (March, 2010).

Inventor and one of the copyright holders of EC-01-002984 "Novel neurological drug of combined valproic acid and topiramate" and **EC-01-002980** "Topical use of berberine in treatment of male sexual disorders such as premature ejaculation and/or erectile disfunction" (internationally registered by INTEROCO copyright office, October, 2020).

Editor of Anticoagulation Drugs - the Current State of the Art, ISBN: 978-1-78985-076-5 (March, 2020)

I've been invited as a speaker to more than 150 international medical conferences and as an organizing committee member to more than 10 international medical conferences all over the world and I'm a current member of the editorial boards of several international medical journals e.g. Journal of General Medicine, open access; Journal of Prevention and Infection Control; Journal of Integrative Obesity and Diabetes; International Journal of Diabetes; Diabetes and Metabolism International Journal; Journal of Obesity and Metabolism; International Journal of Diabetes & Metabolic Disorders and Journal of Endocrinology and Disorders.

I've also acted as a reviewer for several international medical journals e.g. British journal of pharmacology; Clinical Pharmacology & Therapeutics; Biomedicine & Pharmacotherapy; Clinical Chemistry and Laboratory Medicine; Frontiers in Pharmacology; Current Research in Pharmacology and Drug Discovery; Therapeutic Advances in Respiratory Disease; Indian Journal of Pharmacy and Pharmacology; International Research Journal of Medicine and Medical Sciences; Pharmacy & Pharmacology International Journal; Current Trends in Pharmacology and Clinical Trials Journal; Journal of Unexplored Medical Data; Diabetes & Obesity International journal; Open Access Journal of Endocrinology (ISSN: 2578-4641); Global Journal of Endocrinological Metabolism (ISSN: 2637-8019); Journal of General and Emergency Medicine and Pediatric Research and Child Health.

13. Academic experience, research interests and teaching philosophy:

Teaching basic, clinical and experimental pharmacology and pharmacotherapy through the **traditional, credit hours as well as the integrated problem-based learning (PBL) methods** in Egypt and KSA to under as well as post graduate students of **medicine, dentistry and nursing** colleges. Teaching **clinical pharmacy (pathophysiology I and II) as well as pharmacology including anatomy and physiology through the credit hours learning system to pharmacy** students in KSA. I'm also researching in pharmacology and medicine since 2006. My MSc thesis was entitled: "Effect of nitro-aspirin versus ezetimibe in experimentally induced fatty liver in rats" and the PhD/MD thesis was entitled: "Effect of some antioxidant, antihypertensive and antidiabetic drugs on the toxicity of some antineoplastic drugs in rats".

I'm interested in searching on pharmacotherapy of COVID-19, diabetes, obesity, NAFLD, cancer, autoimmune diseases as well as pharmacovigilance. **I've also practiced** general medicine, internal medicine and dermatology since my graduation in many clinics, dispensaries and hospitals in Egypt and KSA.

In Jouf University college of medicine, I've been involved in **many administrative committees** e.g. head of policies and procedures committee, member of both quality

and accreditation unit as well as examination committee. I've also served as a **block co-organizer** in both "growth and development" as well as "musculoskeletal" blocks and shared in revising as well as updating the matrix, course specifications, ILOs and content of several blocks and courses.

In Jouf University college of pharmacy, I've been the **course coordinator** of anatomy, pathophysiology I and pathophysiology II. I've also educated physiology II and acted as a member of students' activities as well as examination committees. I've also participated in the teamwork preparing for accreditation and participated in a meeting with Accreditation Council for Pharmacy Education (ACPE) accreditation.

I believe teaching is a gift that is nourished by practice and dedication. Through the years, I've built a reputation among students delivering the sophisticated knowledge in a simplified, yet highly scientific manner and I've been so fortunate to be praised by hundreds of them; now amazing physicians, dentists, pharmacists and nurses. I've also been so keen to develop my clinical capabilities as much as I can to remain updated in practice as well as to provide the highest possible quality of education to my students.

14. Relevant publications and papers:

Mina Kelleni (2020): Diclofenac potassium/nitazoxanide/azithromycin novel COVID-19 protocol used in adults, children and pregnant patients: could it be the magic bullet? Authorea (preprint). DOI: 10.22541/au.160797486.63735316/v1

Mina Kelleni (2020): Does the RECOVERY dexamethasone improve COVID-19 mortality? Authorea (preprint). DOI: 10.22541/au.160684625.54943545/v1

Mina T. Kelleni (2020): SARS CoV-2 adenovirus and RNA based vaccines potential autoimmune complications: could we lower the chances? Authorea (preprint). DOI: 10.22541/au.160677062.20686503/v1

Mina T. Kelleni (2020): Tocilizumab, Remdesivir and Favipiravir repurposed for COVID-19: The Good, The Bad and The Ugly. Authorea (preprint). DOI: 10.22541/au.160677059.91320681/v1

Mina T. Kelleni (2020): Early use of Non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomedicine & Pharmacotherapy. 133: 110982-110982 DOI: 10.1016/j.biopha.2020.110982

Kelleni M.T. (2020): ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror. Inflammopharmacol 28, 1477–1480. DOI: 10.1007/s10787-020-00755-x

Mina T Kelleni (2020): SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality. Journal of infection. DOI: 10.1016/j.jinf.2020.08.018

Mina T. Kelleni, Khalid S. Alharbi, Mohammad M. Al-Sanea (2020): Novel neurological drug of combined valproic acid and topiramate. Registered Copyright, EC-01-002984.

Mina T. Kelleni, Mohammed J. Alenzi, Mohammed H. Elkomy (2020): Topical use of berberine in treatment of male sexual disorders such as premature ejaculation and/or erectile dysfunction. Registered Copyright, EC-01-002980.

Mina T Kelleni (2020): "Remdesivir-Gate for COVID-19". Acta Scientific Gastrointestinal Disorders 3.8: 01

Mina T Kelleni (2020): Breakthrough: Ibuprofen/nitazoxanide/azithromycin: a battle changer personalized COVID-19 telemedicine five days protocol. Authorea (preprint), DOI: 10.22541/au.159285564.49698842

Mina T Kelleni (2020): Hypothesis Article: COVID-19 unexplained mortality in the young adults: could it be due to ACE2 polymorphisms? Authorea (preprint), DOI: 10.22541/au.159242108.86655106

Mina T Kelleni (2020): BCG vaccination for COVID-19: Evidence-based medicine approach. Authorea (preprint), DOI: 10.22541/au.159200635.52487940.

Mina T Kelleni (2020): ACEIs, ARBs, Ibuprofen linked to COVID-19: The other side of the broken mirror. Authorea (preprint), DOI: 10.22541/au.159110364.44447300.

Kelleni M.T. (2020) "Rapid Response: Remdesivir is least likely to be effective for safe treatment of COVID-19: A pharmacovigilant point of view". British Medical Journal 369: m2097rr.

Mina T Kelleni (2020): Ibuprofen potential addition to COVID-19 early management protocols: could it be superior to paracetamol and hydroxychloroquine? Authorea (preprint), DOI: 10.22541/au.158878847.71450719

Mina T Kelleni (2020): Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management *Pharmacol Res.* 157: 104874. DOI: 10.1016/j.phrs.2020.104874

Mina T Kelleni (2020): **Editor** of "Anticoagulation drugs - the Current State of the Art" book: ISBN: 978-1-78985-076-5; Print ISBN: 978-1-78985-075-8

Mina T Kelleni (2020): Introductory Chapter: Anticoagulant Therapy in Clinical Practice - Challenges and Wishes. Anticoagulation drugs - the Current State of the Art" book: ISBN: 978-1-78985-076-5; Print ISBN: 978-1-78985-075-8

Athar M Khalifa, **Mina T Kelleni**, Mahrous A Ibrahim, Medhat M Farag, Gamal A Bakhaat (2020): Protective Effects of Blackberry Juice against Cisplatin-Induced Testicular Toxicity in Rats: Up-Regulation of Bcl-2 Proteins and Androgen Receptors; Accepted for publication in International Medical Journal (IMJ).

Mahrous A Ibrahim, Farooq A Wani, Athar M Khalifa, **Mina T Kelleni**, Marwa M Anwar, Ashok kumar, Mohammed S Ubaidulla (2019): Protective effects of selenium on malathion-induced testicular toxicity in mice. Indian Journal of Animal Research 54(3): 335-341.

Mina T Kelleni (2019): Embrace the Future of Drug Therapy of Diabetes Mellitus: Five Novel Approaches with Remarkable Potentials. Biomed J Sci & Tech Res 13(2)-2019.

Kelleni MT (2018): Role of central and peripheral serotonin in obesity: what to expect in the near pharmacotherapy future? Adv Obes Weight Manag Control. 8(6):291.

Mina T. Kelleni and Mahrous Abdelbasset (2018): Drug Induced Cardiotoxicity: Mechanism, Prevention and Management, Cardiotoxicity, Wenying Tan, IntechOpen, DOI: 10.5772/intechopen.79611.

Kelleni MT (2018): Drug induced malignancy: a focus on pioglitazone. Pharm Pharmacol Int J. 6(4):296–298.

Mina T Kelleni (2018): Betaine potentials to prevent diabetes and diabetic complications: what hindered the favorable clinical trial outcomes and what to do? Diabetes Obes Int J 3(3): 000815.

Mina T Kelleni (2018): Vitamin D link to diabetes and obesity: Interesting promising and opposing results to be followed up. Curr Res Diabetes Obes J 8(1): CRDOJ.MS.ID.555734

Kelleni MT (2018): Using subcutaneous insulins to manage mild to moderate diabetic ketoacidosis: a simpler protocol that may save millions in the developing world. Open Access J Endocrinol 2(3): 000128.

Mina T Kelleni (2018): Pioglitazone: An Ongoing Misery in the Developing Countries to Which I can't be Pragmatic!. J Endocrinol 2(2): 000122.

Kelleni MT (2018) HCV Infection in Pediatric Population A Current Brief Synopsis. Pediatr Res Child Health 1: 001-001.

Mina T Kelleni (2018): Using insulin glargine temporarily to control resistant hyperglycemia induced by mild to moderate bacterial infections in Egyptian type 2 diabetic out patients. A real life experience. Gen Med (Los Angeles) 6(1): e116.

Mina T Kelleni (2018): Back to oral hypoglycemic drugs after ten years of insulin injections; An Egyptian case study. J Clin Exp Endocrinol 2(1): e105

Mina T Kelleni (2017): Sublaboratory hypothyroidism in Egyptian young adult females with normal TSH levels; what to do? A practical real life experience. J Gen Emerg Med 2(6): 102e.

Kelleni MT (2017): Diabetogenic Drugs and Hormones, what Every Physician should know and be Aware of? Gen Med (Los Angeles) 5: e114.

Mina T Kelleni (2017): Autoimmune Cholangiopathy at a Glance: Diagnosis, Differential Diagnosis and Treatment. Acute Chronic Dis,1:1. 1000e102.

Mina T Kelleni (2017): Idiopathic Hypereosinophilic Syndrome: Etiology, Diagnosis, Manifestations and Management. J Endocrinol Thyroid Res. 2017; 2(3): 555586.

Mina T. Kelleni (2017): Islet Cell Transplantation for Treating Type 1 Diabetes: The Bright Future of Drug Designing and Development. Nov Appro Drug Des Dev 1(3): NAPDD.MS.ID.555564

Kelleni MT (2017): How the brain-gut axis may connect several cerebro-intestinal co-morbidities: Irritable bowel syndrome and Epilepsy as examples? Int J Gen Med Surg 1(1): 1-3.

Mina T Kelleni (2017): Benefits of green coffee beans extract in health and obesity. SF Obesity Res J 1:1.

Mina T. Kelleni (2017): Avian flu suspected upcoming pandemic: prevention and management. SF J Flu Sci 1:1.

Kelleni MT (2017): Use of Insulin Glargine and Metformin for Prevention of Diabetes and its Cardiovascular Complications. Diabetes Obes Int J 2(2): 000148.

Ibrahim S, Kamel MY, **Kelleni MT** (2017): Effect of nifedipine and glibenclamide addition in a model of high fat dietinduced hypertension and hyperlipidemia in rabbits receiving donepezil. Int J Sci Res Environ Sci Toxicol 2(1): 4.

Mina T. Kelleni (2017): Type 2 Diabetes Mellitus: a reciprocal mutual interaction with amyloidosis or a presentation of an isolated primary pancreatic amyloidosis? Integr Obesity Diabetes, 3(1): 1-2. doi: 10.15761/IOD.1000165

Kelleni MT (2017): General Medicine, Open Access: A Wonderful 2016 Harvest and New Heights to Look Forward In 2017. Gen Med (Los Angeles) 5:1000e112.

Mina T. Kelleni (2016): Gliflozins: initial review of literature. Integr Obesity Diabetes 2(5): 276-276. DOI: 10.15761/IOD.1000159

Mina T. Kelleni (2016): Pre-Dorsal Myxedema: A Rare Unique Manifestation of Hypothyroidism in an Egyptian Female Patient. J Gen Emerg Med 1(1): 101e.

Mina T Kelleni (2016): Sofosbuvir/Simeprevir Induced Fatal Thrombocytopenia in a 47 Years Old Egyptian Patient. Gen Med (Los Angeles) 4:e111

Kelleni MT (2016): A rapid and successful corticosteroid based approach used to treat resistant Alopecia Areata Sisaipho in a 7 years old Egyptian girl; when pediatrics equals grace. Ped Health Res. 1:1.

Mina TK (2016): Amyloid Deposits: a Possible Link between Type 2 Diabetes Mellitus and Cancer. Diabetes Obes Int J 1(6): 000131.

Kelleni MT (2016): Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management? Gen Med (Los Angeles) 4:e110. Doi:10.4172/2327-5146.1000e110

Kelleni MT (2016): Simeprevir, Sofosbuvir and Ribavirin as First Line Therapy of HCV Infection, is it Justifiable Enough Basing on Safety and Efficacy. Gen Med (Los Angel) 4:e109. Doi:10.4172/2327-5146.1000e109

Mina T Kelleni (2016): Amyloid Antagonists: The Future of Type 2 Diabetes as Well as Several Neurodegenerative Diseases Treatments. *Dia Obe Int Jo.* 1(2): 000106.

Mina T Kelleni (2016): Cefotaxime Used as Paracetamol- Antibiotic Resistance in Developing Countries, A Global Upcoming Catastrophe Unless Urgently Addressed. *Journal of Prevention & Infection Control* 2(1): 14.

Mina T Kelleni, Salwa A Ibrahim and Aly M Abdelrahman (2016): Effect of captopril and telmisartan on methotrexate-induced hepatotoxicity in rats: impact of oxidative stress, inflammation and apoptosis. *Toxicol Mech Method.* DOI: 10.1080/15376516.2016.1191576

Kelleni MT (2016) Chamomile Tea Potentials in Prevention and Amelioration of Type 2 Diabetes Mellitus. *J Diabetes Metab* 7:649. DOI:10.4172/2155-6156.1000649

Mina Thabet Kelleni, Entesar F. Amin, Aly M. Abdelrahman (2015): Effect of Metformin and Sitagliptin on Doxorubicin-induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation and Apoptosis. *J Toxicol*, Article ID 424813, 8 pages.

Kelleni MT (2015) Pioglitazone and Sitagliptin: An Urgent Call for New Regulations Controlling all the Post Marketing Drug Safety Studies. *Endocrinol Metab Int J* 2(4): 00029. DOI: 10.15406/emij.2015.02.00029

Mina T Kelleni (2015) A Peculiar Juvenile Progressive Systemic Sclerosis Case Report: The Egyptian versus the International Approach of Treatment. *Gen Med (Los Angel)* S2:005. DOI:10.4172/2327-5146.1000S2-005

Kelleni MT (2015) Fludarabine Monotherapy Fails to Control a Case of Relapsing Non-Hodgkin's Lymphoma. *Gen Med (Los Angel)* 3:204. DOI:10.4172/2327-5146.1000204

Kelleni MT (2015) Together towards an early global detection of type 2 diabetes using a simplified metabolomics' test. Integr Obesity Diabetes. 1: DOI: 10.15761/IOD.1000121

Kelleni MT (2014) Pioglitazone: How Pharmacology Can be used Interchangeably with Mammonology in the Developing Countries? J Diabetes Metab 5 (8):411

Mohamed Ibrahim, **Mina Kelleni**, Ayman Geddawy (2013) Nonalcoholic fatty liver disease: Current and potential therapies. Life Sci. 7; 92(2):114-8.

Mohamed Ibrahim, Entesar Farghaly, Wafaey Gomaa, **Mina Kelleni**, Aly Mohamed Abdelrahman (2011) Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. Eur J Pharm, 659: 289-295.

Mohamed Ibrahim, Entesar Farghaly, Wafaey Gomaa, **Mina Kelleni**, Aly Abdelrahman (2010) Ezetimibe inhibits proinflammatory mediators involved in the pathogenesis of non alcoholic fatty liver disease. Egypt. J. Med Sci, 31 (1): 247-269.